Protein & Cell >

2022 , Vol. 13 >Issue 9: 689 - 693

DOI: https://doi.org/10.1007/s13238-021-00883-2

LETTER

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

  • Yao Zhao 1 ,
  • Chao Fang 2 ,
  • Qi Zhang 1,3,4 ,
  • Ruxue Zhang 5 ,
  • Xiangbo Zhao 2 ,
  • Yinkai Duan 1 ,
  • Haofeng Wang 1 ,
  • Yan Zhu 1 ,
  • Lu Feng 1 ,
  • Jinyi Zhao 1 ,
  • Maolin Shao 1 ,
  • Xiuna Yang 1 ,
  • Leike Zhang 5 ,
  • Chao Peng 6 ,
  • Kailin Yang 7 ,
  • Dawei Ma , 2 ,
  • Zihe Rao , 1,8,9 ,
  • Haitao Yang , 1
Expand
  • 1. Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
  • 2. State Key Laboratory of Bioorganic & Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200032, China
  • 3. CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China
  • 4. University of Chinese Academy of Sciences, Beijing 100049, China
  • 5. State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China
  • 6. National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201210, China
  • 7. Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
  • 8. Laboratory of Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100091, China
  • 9. State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Response, College of Life Sciences, Nankai University, and Tianjin Key Laboratory of Protein Sciences, Tianjin 300071, China

Accepted date: 26 Sep 2021

Published date: 15 Sep 2022

Copyright

2021 The Author(s)
Fold

Cite this article

Yao Zhao , Chao Fang , Qi Zhang , Ruxue Zhang , Xiangbo Zhao , Yinkai Duan , Haofeng Wang , Yan Zhu , Lu Feng , Jinyi Zhao , Maolin Shao , Xiuna Yang , Leike Zhang , Chao Peng , Kailin Yang , Dawei Ma , Zihe Rao , Haitao Yang . Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332[J]. Protein & Cell, 2022 , 13(9) : 689 -693 . DOI: 10.1007/s13238-021-00883-2

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H et al (2021) Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19. BbioRxiv 1: 2020- 2029

2
Cui W, Yang K, Yang H (2020) Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19. Front Mol Biosci 7: 616341

DOI

3
Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F et al (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368: 1331- 1335

DOI

4
Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P et al (2020) Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11: 4417

DOI

5
Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, He M, Hogan RJ, Kozminski K, Li LY et al (2020) Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem 63: 12725- 12747

DOI

6
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C et al (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582: 289- 293

DOI

7
Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, Abeles SR, Torriani FJ (2021) Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med 384: 1774- 1775

DOI

8
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565- 574

DOI

9
Manns MP, von Hahn T (2013) Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12: 595- 610

DOI

10
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF (2021) Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol 21: 626- 636

DOI

11
Vandyck K, Deval J (2021) Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol 49: 36- 40

DOI

12
Wang F, Chen C, Tan W, Yang K, Yang H (2016) Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design. Sci Rep 6: 22677

DOI

13
Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J et al (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3: e324

DOI

14
Zhao Y, Du X, Duan Y, Pan X, Sun Y, You T, Han L, Jin Z, Shang W, Yu J et al (2021) High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell https://doi.org/10.1007/s13238-021-00836-9

15
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054- 1062

DOI

Options
Outlines

/

〈 〉